Emeramed NMBI being approved for Metals Detoxification from freeamfva's blog

Emeramed NMBI being approved for Metals Detoxification

Emeramed is pursuing regulatory approval of an orphan drug, currently known as NBMI. The drug has also been known as OSR, Irminix and Emeramide. It has performed successfully in chelating mercury and iron, and is known to have an affinity for chelating cadmium, lead and arsenic. NBMI is unlike any protocol used to date for those who are familiar with other methods of removing heavy metals. To get more news about Buy emeramide, you can visit fandachem.com official website.

For those toxic who have used other chelation methods and understand the harsh side effects they most often provide, NBMII has none of the same side effects. NBMI attaches to the metal and is able to render it inert and therefore, it can no longer harm the body or organs as it exits. It has the unique benefit of leaving the body via the colon, and so, does not harm vital organs as other methods can. This means kidney damage, familiar with other metals detoxing methods, is no longer a danger.

Another primary benefit of NBMI is that once chelated to the metal in the body, it will not detach or be or dropped, which would allow it to be an active contaminant again. This means there is no possible chance of reabsorption into the system and so, there is no side effect of the usual reabsorption symptoms as with other detoxing methods.

NBMI has the ability to access metal storage in fat tissue. It will also cross the blood-brain barrier to clear the brain. It does not cause a significant loss of essential metals in the body and has been shown to be a powerful antioxidant which assists with fatigue and health problems created by contamination. There is no depletion of energy or resources while chelation is taking place. In fact, the body might feel energized and begin feeling a new level of wellness very soon.

The product has been used in Ecuador on workers who use mercury in the course of mining gold. Their progress has been remarkable. The government is pursuing NMBI, which is known as Irminix in South America, for continued use.

The Swedish government is using NBMI for the treatment of COPD. Because COPD is suspected to be related to cadmium toxicity in the lungs, the hope is that NMBI will provide a sensible treatment plan without side effects. Patients to date report improvement with the treatment. In addition, Slovenia will be using the product for the treatment of Atypical Parkinson’s Disease.

It is important to note that much of what we believe can the future of NBMI has not be tested. The results so far are only for mercury and iron. What is known is that the product has a clear affinity for mercury and will attach to it first before other metals when it is available. It is suspected that lead and arsenic will be sought by NBMI after all available mercury is chelated, but these are not statements Emeramed can make at this point.

Because mercury affects the central nervous system there are many potential reactions to it. It is associated with autism, Parkinson’s, Alzheimer’s, Multiple Sclerosis and hundreds of other symptoms and conditions without confirmation from Western medicine. Those metals poisoned claim a vast number of symptoms that seem to confirm a variety of similar issues.